What is Aquestive Therapeutics, Inc.'s SG&A?

Aquestive Therapeutics, Inc. (AQST) reported SG&A of $10.98M in Q1 2026.

How has Aquestive Therapeutics, Inc.'s SG&A changed year-over-year?

Aquestive Therapeutics, Inc.'s SG&A decreased by 42.4% year-over-year, from $19.07M to $10.98M.

What is the long-term trend for Aquestive Therapeutics, Inc.'s SG&A?

Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s SG&A has grown at a 10.5% compound annual growth rate (CAGR), from $53.48M to $79.85M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Aquestive Therapeutics, Inc. AQST SG&A

SG&A at other companies

Indivior Pharmaceuticals, Inc. INDV

$124M-6.8%

ARS Pharmaceuticals, Inc.SPRY

$72.2M+75.7%

ViatrisVTRS

$928.8M-2.0%

AbbVieABBV

$3.58B+8.7%

Absci CorporationABSI

$9.06M-4.4%

PrecigenPGEN

$21.05M+70.3%

Segments

By segment

See full

Reportable Segment$10.98M-42.4%

Other financials

Income statement

See full

Revenue$14.4M+65.7%

Gross profit$11.0M+117%

Operating income-$4.2M+78.3%

Net income-$8.1M+64.9%

EPS (diluted)-$0.07+70.8%

Balance sheet

See full

Cash & equivalents$110.7M+61.3%

Total debt$64.4M+7.4%

Total equity-$34.1M+44.1%

Total assets$141.1M+38.0%

Cash flow

See full

Operating cash flow-$14.8M+36.7%

CapEx$52.0K-61.5%

Free cash flow-$14.9M+36.9%

Valuation

See full

Market cap$560.13M+73.5%

Enterprise value$513.76M+63.6%

P/S11.1×+5.2×

Profitability

See full

Gross margin63.5%-4.9pp

Operating margin-111.2%+96.3pp

Net margin-137.1%+80.7pp

FCF margin-88.2%-2.2pp

Returns & leverage

See full

Return on equity145.1%—

Debt / equity-1.9×—

Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s SG&A?: Aquestive Therapeutics, Inc. (AQST) reported SG&A of $10.98M in Q1 2026.
How has Aquestive Therapeutics, Inc.'s SG&A changed year-over-year?: Aquestive Therapeutics, Inc.'s SG&A decreased by 42.4% year-over-year, from $19.07M to $10.98M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s SG&A?: Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s SG&A has grown at a 10.5% compound annual growth rate (CAGR), from $53.48M to $79.85M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.